2,843% in a day?!

Jason Stutman explains the network of doctors, analysts, and former bench scientists he's built over the last year, as well as the private catalyst calendar he's put together, and how the combination of the two creates the most compelling trading strategy you'll come across... You are receiving this email because you subscribed to Wealth Daily. [Click here]( to manage your e-mail preferences. [Wealth Daily logo] 2,843% in a day?! [Jason Stutman Photo] By [Jason Stutman]( Written Mar. 30, 2019 Last week I reached out to clue you in on a massive moneymaking opportunity lurking just around the corner. I showed you just how quickly small, development-stage biotech stocks can take off when news of a major impact event breaks. And, more specifically, I highlighted a number of biotech stocks that exploded in March, including: - Ascendis Pharma (NASDAQ: ASND), which climbed 81% in a single day of trading (March 4) - Bio-Path Holdings (NASDAQ: BPTH), which exploded 1,843% (February 8 through March 7) - Axovant Gene Therapies (NASDAQ: AXGT), which climbed 65% in a single day (March 11) - Daré Bioscience (NASDAQ: DARE), up 103.9% in a single day (March 18) - Dermira, Inc. (NASDAQ: DERM), up 87.4% in a single day (March 18) - And PhaseBio (NASDAQ: PHAS), up 88.8% in a single day (March 18) I also told you last week that we were bound to see at least a few more of these events before the month was up. Following through with this prediction, I’ll point you to yet another biotech breakout we saw earlier this week. In fact, I'll give you two... Bank 1,000% on the Death of Comcast America’s most hated cable company is standing on its last leg. And it’s not because of terrible customer service or mediocre products. It’s because of a technological shift that’s scheduled to start in late-2018. It's a shift that could earn you 1,000% gains as three companies bring down big cable. [Click here for their ticker symbols.]( On Tuesday, March 26, a small biotech company by the name of Aldeyra Therapeutics (NASDAQ: ALDX) skyrocketed 79% in a single day, after announcing positive Phase 3 results for its lead drug candidate, reproxalap, as a potential treatment for “allergic conjunctivitis.” “Allergic conjunctivitis” is the clinical term for dry and itchy eyes caused by allergic reactions, but the terminology honestly isn’t that important. What matters to you is that the company took off on the release of clinical trial results, as so many biotech stocks do after the release of top-line data or regulatory decisions. Also this week, we saw Seelos Therapeutics (NASDAQ: SEEL) release an update on its drug pipeline, leading to a 30% gap open Friday morning. Now, I challenge anyone reading this to present a segment of the stock market that produces consistent gains as big as these and in such short periods of time... That challenge, of course, is rhetorical. Nowhere else will traders find such massive one-day stock returns as they will in development-stage biotech. Nowhere else, either, are these kinds of moves telegraphed so clearly by a schedule of upcoming catalyst events. As I mentioned last week, my team and I have developed a trading strategy to leverage these kinds of events for maximum profit, and I’ll be sharing all the details in a free, limited-time webinar that will air on April 18. You see, for more than a year, I’ve been building a network of doctors, analysts, and former bench scientists who have worked in the very same kinds of labs that innovative drugs are being developed in today. Jointly, I’ve put together a private calendar, marking down critical catalyst dates of small biotech stocks that most people will never even know the name of. Put the two together, and you get what is easily the single most compelling trading strategy I’ve come across in my entire career. By tracking the global drug development pipeline, we’re able to get in before these events happen and ride the hype for stock returns most investors can only dream of. [Peter Thiel Made Billions In 62 Days...]( Peter Thiel is the first of the famous billionaires to make more than a billion dollars off of cannabis. But would you expect anything less? He’s the investor who made billions on PayPal, then Facebook, then Airbnb, and then Lyft. Which is why I took careful note when he put $1.2 billion into the marijuana company Tilray, Inc. The moment it went public, it shot up more than tenfold in just 62 days, making his stake worth a whopping $12 billion. As Bloomberg reported, it was an instant win for Peter Thiel... and for all the insiders who followed his lead. But he’s far from done... I know for a fact he’s been looking at new buyouts, and the five cannabis stocks on my list are prime candidates. [Click here to make money on Peter Thiel’s next buyout.]( One thing I didn’t mention last week, by the way, is a calculation we’ve developed called “Chance of Success.” We’ll get into the full details during the webinar on April 18, but understand for now that this number tells us exactly how likely a drug is to make it through FDA approval, down to a single percentage point. Our team takes every detail into account when determining the Chance of Success of a drug or medical device. We look at what kind of drug it is, which disease is being targeted, the method of delivery, and, of course, all the available trial data. We then adjust off historical baselines for the most accurate risk assessment possible. Our analysis goes so far that it will even take into account the voting history of the individuals who are sitting on the FDA panels, making the final regulatory decisions. Ultimately, this means we know when to take and when to avoid certain risks. For instance, we have the option of only betting on drug candidates with a 90% approval chance or higher. In fact, some of the catalysts we're currently looking at have chance of approvals as high as 99%. Nothing comes without risk trading on the market, of course, but these odds are the best I’ve ever come across by a long shot. Registration for this event is just around the corner, so keep an eye open for the next couple weeks. We’re still putting together the final bonus materials, but early registrants will be receiving a free podcast, early access, and critical information on the drug development process that will allow you to leverage these events for maximum profit. More on all this next week. Until next time, [JS Sig] Jason Stutman [follow basic]( [@JasonStutman on Twitter]( Jason Stutman is Wealth Daily's senior technology analyst and editor of investment advisory newsletters Technology and Opportunity and The Cutting Edge. His strategy for building winning portfolios is simple: Buy the disruptor, sell the disrupted. Covering the broad sector of technology and occasionally dabbling in the political sphere, Jason has written hundreds of articles spanning topics from consumer electronics and development stage biotechnology to political forecasting and social commentary. Outside the office Jason is a lover of science fiction and the outdoors, and an amateur squash player at best. He writes through the lens of a futurist, free market advocate, and fiscal conservative. Jason currently hails from Baltimore, Maryland, with roots in the great state of New York. Enjoy reading this article? [Click here]( to like it and receive similar articles to read! Browse Our Archives [CBD: Miracle Molecule or Snake Oil?]( [What's Going on at Tesla?]( [The Time Has Finally Come: A Lyft IPO]( [Uber Wants Your Money, Part Duh]( [The Secret to Quick and Easy Biotech Stock Returns]( --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Wealth Daily, please add newsletter@wealthdaily.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. [Wealth Daily](, Copyright © 2019, [Angel Publishing LLC](. All rights reserved. 111 Market Place #720 Baltimore, MD 21202. The content of this site may not be redistributed without the express written consent of Angel Publishing. Individual editorials, articles and essays appearing on this site may be republished, but only with full attribution of both the author and Wealth Daily as well as a link to www.wealthdaily.com. Your privacy is important to us -- we will never rent or sell your e-mail or personal information. [View our privacy policy here.]( No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. [Wealth Daily]( does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question.